ScholarIQanswers from OpenAlex & ORCID
Michael Boyer
ResearcherPublications, citations & collaboration network
Michael Boyer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael Boyer have?
ScholarIQindexed works
Michael Boyer has 612 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael Boyer have?
ScholarIQcitation count
Michael Boyer has 51,658 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael Boyer?
ScholarIQh-index
Michael Boyer has an h-index of 79 in OpenAlex.
What is the i10-index of Michael Boyer?
ScholarIQi10-index
Michael Boyer has an i10-index of 242 in OpenAlex.
What is the ORCID of Michael Boyer?
ScholarIQorcid
The ORCID for Michael Boyer is on the source record.
What is the OpenAlex record for Michael Boyer?
ScholarIQopenalex
The OpenAlex for Michael Boyer is on the source record.
What are the most-cited papers on Michael Boyer?
ScholarIQmost cited works
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist